Valeant?s ?Tough Tactics? in Drug Pricing Drawing Attention

October 5, 2015

The New York Times (Pollack, Tavernise, 10/5, subscription publication) profiled the “tough tactics” of Valeant Pharmaceuticals, citing the company’s decision to increase the price of Cuprimine (penicillamine) over 400% as an example of its “concerted strategy” of “buying up existing drugs and raising prices aggressively, rather than trying to develop new drugs.” Although the company’s strategy has “richly rewarded its investors,” it has also “drawn the ire of lawmakers and helped stoke public outrage against the growing trend of higher and higher drug prices imposed by big drug companies.”